# Intermittent antibiotic exposure of Escherichia coli biofilms drives resistance in catheter-associated infection models

**Authors:** Yutaka Yoshii, Stanislas Thiriet-Rupert, David Lebeaux, Jean-Marc Ghigo, Christophe Beloin

PMC · DOI: 10.1038/s41522-025-00906-4 · 2026-01-17

## TL;DR

Intermittent antibiotic use on biofilms can lead to antibiotic resistance, while continuous treatment avoids this issue.

## Contribution

The study reveals that intermittent antibiotic exposure promotes resistance in biofilms through specific mutations.

## Key findings

- Continuous antibiotic therapy eradicates E. coli biofilms without resistance emergence.
- Intermittent therapy selects for low-level amikacin-resistant mutants via fusA, sbmA, and cpxA mutations.
- Low-level resistance in biofilms may contribute to high-level resistance in clinical settings.

## Abstract

The use of antibiotic lock therapy (ALT) to protect catheters from infection is still being debated due to its inconsistent effectiveness and the potential risk of promoting antibiotic resistance. Using an in vitro infection model of a pediatric venous access port, we demonstrated that 10 days of continuous therapy eradicates Escherichia coli biofilms in vitro without the emergence of antibiotic resistance. By contrast, an 8-h intermittent therapy used for infected parenteral nutrition patients rapidly selected low-level amikacin-resistant mutants both in vitro and in vivo in a clinically relevant rat model, primarily due to convergent fusA, sbmA, and cpxA mutations. Our findings indicate that intermittent dosing generates pulsed selective pressure, favoring the development of resistance mutants within spatially structured biofilm communities. This suggests that biofilms may act as evolutionary incubators, in which medical interventions could unintentionally influence adaptation outcomes. Furthermore, the low-level resistance developing in treated biofilms may be overlooked in clinical settings and contribute to the selection of high-level resistant mutants. Our study, therefore, underscores that, in addition to dosing, optimizing the timing of antimicrobial treatment could mitigate the emergence of resistance. These principles are applicable beyond catheters to any biofilm-related infections where short-term antibiotic exposure may impact microbial community adaptation.

## Linked entities

- **Genes:** fusA (elongation factor G) [NCBI Gene 884230], AR (androgen receptor) [NCBI Gene 367], cpxA (two-component system sensor histidine kinase CpxA) [NCBI Gene 914983]
- **Chemicals:** amikacin (PubChem CID 37768)
- **Diseases:** infection (MONDO:0005550)
- **Species:** Escherichia coli (taxon 562), Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** infected (MESH:D007239)
- **Chemicals:** amikacin (MESH:D000583)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12894844/full.md

---
Source: https://tomesphere.com/paper/PMC12894844